A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology

Volumn 17, Issue 6, 2006, Pages 1007-1013

  Kollmannsberger, C ^a,b   Schittenhelm, M ^a   Honecker, F ^a   Tillner, J ^c   Weber, D ^c   Oechsle, K ^a   Kanz, L ^a   Bokemeyer, C ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c MERCK KGAA   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

EMD 72000; Lung cancer; Matuzumab; Paclitaxel; Phase I

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MATUZUMAB; PACLITAXEL; RANITIDINE;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HOT FLUSH; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN FISSURE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33646870539     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl042     Document Type: Article

References (32)

1. Anonymous. Chemotherapy for non-small cell lung cancer:NOn-small cell lung cancer Collaborative Group. Cochrane Database of Systematic Reviews 2000; VD002139.
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
3. Ciardiello F. An update of new targets for cancer treatment: receptor-mediated signals. Ann Oncol 2002; 13: 29-38.
4. Rusch V, Baselga J, Cordo-Gardo J et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53 (Suppl 10): 2379-2385.
5. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
6. Chen Z, Ke LD, Yuan XH, Adler-Storthz K. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 2000; 20: 899-902.
7. Montgomery R, Guzman J, O'Rourke O, Stahl W. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 2000; 275: 17358-17363.
8. Cooke T, Reeves J, Lanigan A et al. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001; 12 (Suppl 1): S23-S28.
9. Scambia G, Benedetti Panici P, Ferrandina G et al. Prognostic significance of receptors for epidermal growth factor, estrogen, and progesterone in ovarian cancer. Ann NY Acad Sci 1996; 784: 202-208.
10. Dassonville O, Formento JL, Francoual M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-1878.
11. Sirotnak FM, Zakowski MF, Miller VA et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.
12. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53: 4322-4328.
13. Yang XD, Jia XC, Corvalan JR et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
14. Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North America 2002; 16: 1041-1063.
15. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: Small molecules, big hopes. J Clin Oncol 2002; 20: 2217-2219.
16. Matar P, Rojo F, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10: 6487-6501.
17. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
18. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004; 350: 2129-2139.
19. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-1167.
20. Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-184.
21. Burger A, Heiss NS, Kreysch H-G et al. The humanized monoclonal anti-EGFR antibody EMD 72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Am Ass Cancer Res 2003; 44: 1139 (Abstr 5719).
22. Amendt C, Mantell O, Peters M et al. In vivo activity of humanized monoclonal anti-EGFR antibody EMD72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model. Proc Am Ass Cancer Res 2003; 44: 1234 (Abstr 6180).
23. Gillies S, Lan Y, Wesolowski J et al. The role of ADVV effector function in the anti-tumor efficacy of anti-EGFR antibodies in a mouse xenograft model. Clin Cancer Res 2003; 9: 127 (Abstr B224).
24. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21: 2933-2939.
25. Bonomi P. Review of paclitaxel/carboplatin in advanced non-small cell lung cancer. Semin Oncol 1999; 26: 55-59.
26. Gatzemeier U, von Pawel J, Gottfried M et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 3390-3399.
27. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
28. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002; 29: 55-60.
29. Herbst S, Giaccone G, Schiller J et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794.
30. Cresteil T, Monsarrat B, Alvinerie P et al. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54: 386-392.
31. Leyland-Jones B, Gelmon K, Ayoub JP et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965-3971.
32. Salazar R, Tabernero J, Rojo F et al. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). Proc Am Soc Clin Oncol 2004; 23: 127 (Abstr 2002).